Compare GRFS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | LEGN |
|---|---|---|
| Founded | 1940 | 2014 |
| Country | Spain | United States |
| Employees | 23800 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.9B |
| IPO Year | N/A | 2020 |
| Metric | GRFS | LEGN |
|---|---|---|
| Price | $8.67 | $18.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $10.15 | ★ $63.46 |
| AVG Volume (30 Days) | 560.8K | ★ 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.47 | $67.72 |
| Revenue Next Year | $4.92 | $43.82 |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.19 | $16.24 |
| 52 Week High | $11.14 | $45.30 |
| Indicator | GRFS | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 41.00 |
| Support Level | $8.24 | $16.24 |
| Resistance Level | $9.11 | $23.68 |
| Average True Range (ATR) | 0.28 | 0.88 |
| MACD | -0.07 | 0.18 |
| Stochastic Oscillator | 25.50 | 8.09 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.